LuciOsim 80 MG (Osimertinib)

Description

Osimertinib

Each film-coated LuciOsim tablet contains: Osimertinib … 80mg

INDICATIONS

The treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA approved test and the treatment of patients with metastatic EGFR T790M mutation -positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.

DOSAGE

Recommended dosage: 80mg orally once daily, with or without food.

STORAGE

Store at 20°C to 25°C (77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

MANUFACTURED AND MARKETED BY

LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.